Millions of people enrolled in Medicare prescription drug plans now pay nothing out of pocket for shingles shots, RSV vaccines, and other adult immunizations recommended by federal health advisors. The zero-cost rule, a provision of the Inflation Reduction Act, took effect on January 1, 2023, and applies to any adult vaccine endorsed by the Advisory Committee on Immunization Practices that is not already covered under Medicare Part B. The change eliminated copays that had previously discouraged some older adults from getting vaccinated, though questions persist about whether beneficiaries actually know the financial barrier is gone.
How the IRA erased vaccine copays for Part D enrollees
Before 2023, Medicare Part D plans could charge cost-sharing for vaccines such as the two-dose shingles series, which often ran well over $100 per dose at retail pharmacies. The Inflation Reduction Act required Part D sponsors to drop that cost-sharing to zero for every adult vaccine endorsed by ACIP starting January 1, 2023. That single rule change covered a wide range of immunizations, from shingles and hepatitis B to tetanus boosters, all at no charge to the enrollee.
RSV vaccines for older adults entered the picture a few months later. On June 21, 2023, ACIP voted to recommend RSV vaccination for adults aged 60 and older, and the CDC Director endorsed that recommendation shortly after. Because the IRA ties Part D coverage to ACIP endorsement, the RSV shot for seniors became eligible for zero cost-sharing as soon as the recommendation was finalized. That sequence matters: the speed at which a new vaccine moves from advisory-committee vote to no-cost coverage is now built into the law rather than left to individual plan decisions.
Savings are real, but uptake data remains thin
The HHS Office of the Assistant Secretary for Planning and Evaluation published an analysis using CMS prescription drug event data and enrollment records to estimate how much Part D enrollees saved once vaccine cost-sharing disappeared. The report confirmed that the policy produced measurable dollar savings for beneficiaries who previously faced copays or coinsurance at the pharmacy counter, particularly for high-cost vaccines such as shingles.
What the available evidence does not yet show is whether those savings translated into significantly higher vaccination rates. No published CMS dataset breaks out 2024 shingles or RSV claim volumes by plan type, and no primary data tracks whether individual Part D sponsors sent targeted outreach letters telling members about the zero-dollar benefit. Without standardized reporting on plan-level education campaigns, it is difficult to compare outcomes across insurers or regions.
The hypothesis that plans with direct beneficiary outreach would see higher claim volumes than plans relying only on provider education is plausible, but it cannot be confirmed with the public record available as of mid-2026. The most recent government analyses predate the current season, so any present-tense claims about uptake trends would outrun the data. For now, policymakers can say with confidence that the law removed a clear financial barrier; they cannot yet quantify how much that change has shifted behavior.
What Part D enrollees should do right now
The practical gap is awareness. Medicare’s own consumer pages confirm that Part D covers shingles and other ACIP-recommended vaccines at no cost to the beneficiary, but not every enrollee regularly checks online guidance. Some older adults still assume they will face a substantial bill at the pharmacy counter, especially if they remember paying for the same shot a few years ago.
Beneficiaries who are unsure about their coverage can start with a few straightforward steps. First, they can call the customer service number on the back of their Part D or Medicare Advantage card and ask specifically whether shingles, RSV, and other recommended adult vaccines are covered with zero copay. Plan representatives should be able to confirm the benefit and identify in-network pharmacies that can administer the shots.
Second, enrollees can talk with their primary care clinicians or pharmacists about which vaccines they need based on age and health status. Because the IRA ties coverage to ACIP recommendations, the list of eligible vaccines may expand over time as new products are approved and endorsed. A brief conversation during an annual wellness visit or routine prescription pickup can help ensure that needed shots are not overlooked.
Finally, Medicare beneficiaries who help family members with health decisions can share what they learn. Informal word-of-mouth remains a powerful channel in older communities, and explaining that previously expensive vaccines are now free at the point of care may prompt friends or relatives to ask their own doctors about getting up to date.
The policy change is clear: for adults with Medicare drug coverage, cost should no longer be the reason to skip a recommended vaccine. The remaining challenge is making sure people know that the barrier has been removed-and then turning that knowledge into action at the clinic or pharmacy.
